Advertisement

Topics

LYSOGENE Company Profile

15:22 EDT 24th September 2018 | BioPortfolio

LYSOGENE is a clinical stage biotechnology company committed to the development and commercialization of innovative therapies for patients affected with rare disorders and high unmet medical needs. LYSOGENE’s team translated its rAAVrh10 lead product for Sanfilippo from bench to bedside in an unprecedented fashion over the last years. Its lead product is for Sanfilippo syndrome, a neurodegenerative lysosomal storage disorder considered to be a perfect model for gene therapy. LYSOGENE is currently expanding its pipeline to additional diseases with high unmet medical needs. Lysogene was launched in 2009. It completed a Series A financing in May 2014 with leading life sciences investors Sofinnova Partners, BPI Innobio and Novo AIS.


News Articles [11 Associated News Articles listed on BioPortfolio]

Lysogene and others partner to develop gene therapy for Fragile X

Lysogene Reports First Quarter Financial Results and Provides Business Update

Extended CNS pipeline with a collaboration agreement for the development of an AAV-based gene therapy for Fragile X syndrome, the most common single gene cause of autism, a condition of high un...

Lysogene Strengthens Board of Directors with Appointment of Dr. Peter Lichtlen

CAMBRIDGE, Mass. and PARIS, April 23, 2018 (GLOBE NEWSWIRE) -- Lysogene (FR0013233475 – LYS), a leading biopharmaceutical company pioneering gene therapy technologies to treat central nervous s...

Lysogene Announces Upcoming Presentations at the 2018 International MPS symposium

CAMBRIDGE, Mass. and PARIS, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Lysogene (FR0013233475 – LYS), a pioneering biopharmaceutical company specializing in gene therapy targeting central nervous system (...

Lysogene Reports Second Quarter Cash Position and Provides Business and Strategic Update

CAMBRIDGE, Mass. and PARIS, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Lysogene (FR0013233475 – LYS), a pioneering biopharmaceutical company specializing in gene therapy targeting central nervous system (...

Lysogene Announces the Nomination of Dr. Ralph Laufer as Chief Scientific Officer and Member of the Executive Team

CAMBRIDGE, Mass. and PARIS, May 15, 2018 (GLOBE NEWSWIRE) -- Lysogene (FR0013233475 – LYS), a pioneering biopharmaceutical company specializing in gene therapy targeting central nervous system (C...

Lysogene Signs Partnership Agreement with Dr. Hervé Moine, Researcher at the IGBMC(1) and the SATT(2) Conectus Alsace, in the Fragile X Syndrome

Development of a gene therapy product for the treatment of patients with Fragile X syndromeImplementation of the project through a unique partnershipFirst results anticipated in 2019 ...

Lysogene Announces the Nomination of Dr Ralph Laufer as Chief Scientific Officer and Member of the Executive Team

Regulatory News: Lysogene (Paris:LYS) (FR0013233475 – LYS), a pioneering biopharmaceutical company specializing in gene therapy targeting central nervous system ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

LYSOGENE

LYSOGENE is a clinical stage biotechnology company committed to the development and commercialization of innovative therapies for patients affected with rare disorders and high un...

More Information about "LYSOGENE" on BioPortfolio

We have published hundreds of LYSOGENE news stories on BioPortfolio along with dozens of LYSOGENE Clinical Trials and PubMed Articles about LYSOGENE for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of LYSOGENE Companies in our database. You can also find out about relevant LYSOGENE Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...


Corporate Database Quicklinks



Searches Linking to this Company Record